The pharma giant wants to refreshen its portfolio after some of its internal development programs disappointed in clinical ...

A readily available sleep aid has been shown to have a surprising side effect on brain health, seemingly protecting the organ ...

Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing ...

Scientists discovered a new way to protect memory in Alzheimer's by targeting the blood-brain barrier instead of amyloid ...

HSV-1 infection may be linked to the risk for Alzheimer’s disease, but antiviral treatment may be protective, a large ...

Treating cold sores with anti-viral medicines could help slash the risk of Alzheimer’s disease, research suggests. Previous ...

TREATING cold sores with anti-viral medicines could slash the risk of Alzheimer’s disease by 17 per cent, research suggests. Previous studies have found that the herpes simplex virus – ...

Researchers have found that the herpes virus, which causes cold sores, increases Alzheimer’s risk by as much as 80% by ...

Sanofi has announced that it will be acquiring Vigil Neuroscience and its investigational Alzheimer’s disease (AD) drug for ...

More info There has never been “such positivity” about treatments for Alzheimer’s, and big changes will ... was recently approved by the European Medicines Agency (EMA).

The FDA cleared the test for early detection of amyloid plaques associated with Alzheimer’s in people aged 55 years and older ...

Proposed intravenous maintenance dosing application to reduce lecanemab infusion frequency from every two weeks to every four weeks for eligible adult UK patients after initial 18 months of treatment ...